Ming Hsieh Sells 2,227 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Ming Hsieh sold 2,227 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $18.26, for a total value of $40,665.02. Following the transaction, the chief executive officer now owns 703,711 shares in the company, valued at $12,849,762.86. This represents a 0.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Fulgent Genetics Price Performance

Fulgent Genetics stock opened at $18.07 on Friday. Fulgent Genetics, Inc. has a fifty-two week low of $16.56 and a fifty-two week high of $30.68. The stock has a 50-day simple moving average of $19.86 and a 200-day simple moving average of $21.14.

Wall Street Analysts Forecast Growth

FLGT has been the topic of several research reports. StockNews.com downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday. Piper Sandler dropped their price objective on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Monday, November 11th.

Hedge Funds Weigh In On Fulgent Genetics

Several institutional investors have recently added to or reduced their stakes in FLGT. Vanguard Group Inc. increased its position in Fulgent Genetics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,424,448 shares of the company’s stock worth $30,911,000 after purchasing an additional 8,257 shares during the period. Millennium Management LLC increased its position in Fulgent Genetics by 34.3% during the 2nd quarter. Millennium Management LLC now owns 958,852 shares of the company’s stock worth $18,813,000 after purchasing an additional 244,981 shares during the period. State Street Corp increased its position in Fulgent Genetics by 1.4% during the 3rd quarter. State Street Corp now owns 793,545 shares of the company’s stock worth $17,244,000 after purchasing an additional 10,868 shares during the period. Divisadero Street Capital Management LP grew its holdings in shares of Fulgent Genetics by 46.4% in the 2nd quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock worth $9,912,000 after acquiring an additional 160,212 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Fulgent Genetics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 502,869 shares of the company’s stock worth $10,930,000 after acquiring an additional 13,320 shares during the period. Institutional investors and hedge funds own 48.06% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.